

2024 PIPELINE CONFERENCE

September 25-26, 2024

Signia by Hilton, Atlanta Georgia

Wednesday, September 25

7:00-8:15 Breakfast and Registration

8:15 – 8:35 Welcome and Introduction

Jacqueline French, MD, Chief Medical and Innovation Officer, Epilepsy Foundation

Bernice Martin Lee, CEO, Epilepsy Foundation: Our Health Equity Imperative

William Theodore, MD, President, American Epilepsy Society

Helen Cross, MD, President, International League Against Epilepsy

SESSION I: PRECLINICAL

Moderator: Priya Balasubramanian PhD

8:35-8:50 New preclinical models: Are they helping or hurting? **Karen Wilcox, PhD,**
The University of Utah

8:50-9:05 NINDS Epilepsy Therapy Screening Program Updates: **Brian Klein, PhD, NINDS**

9:05-9:20 Automated large scale anti-seizure drug testing: **Tilo Aurelio Gschwind, PhD,**
Stanford University

9:20 – 9:30 Q&A

9:30 – 9:40 LRP-661: **Abdel-Rahman Lawendy, HBSc, MD, FRCSc, PhD,**
London Pharmaceuticals

9:40-9:50 PrevEpP002: **Alexander Rotenberg, MD, PhD, PrevEp**

9:50-10:00 NEUmiRNA Therapeutics: **Janine Erler, PhD**

10:00–10:20 Networking Break

SESSION II: Digital solutions for clinical trials and beyond

Moderator: Caitlin Grzeskowiak PhD

10:20-10:25 Patient/Caregiver Perspective: **Alison Kukla, MPH, Epilepsy Foundation**

10:25-10:40 Considerations from lived experience for monitoring devices: **Tom Stanton, MPS,**
Danny Did Foundation

- 10:40-10:55** From conception to clinical availability - the pathway for tracking and monitoring devices: Judy Lenane, CEO, Neuroinsights, Inc.
- 10:55-11:10** How do you determine that a seizure is a seizure on EEG: Nathan Fountain, MD, University of Virginia
- 11:10-11:30** Towards optimized Seizure diaries as trial outcome tools – Panel Discussion: Ludovic Ampe, Neuroventis; Gail Farfel, PhD; Meryl Lozano, MBE, Epilepsy Study Consortium, Inc.; Alison Kukla, MPH, Epilepsy Foundation; Micaela Forshaw, MPH, Biohaven
- 11:30–11:40** Q&A
- 11:40–12:40** Networking Lunch

SESSION III: DIGITAL SOLUTIONS/DEVICE

Moderator: Nathan Fountain MD

- 12:40–12:45** Patient Perspective : Jessica Hauflaire, Digital Therapeutics Alliance
- 12:45–1:00** Epilepsy Foundation ChatBot: David-Alexandre Jost, Epilepsy Foundation
- 1:00-1:10** Insights from Continuous EEG: Rohan Hoare, BSc, MA, PhD, EpiMinder
- 1:10-1:20** Dreem: Jay Pathmanathan, MD, PhD, Beacon Biosignals
- 1:20-1:30** Epiness: Oren Shriki, PhD, NeuroHelp
- 1:30-1:40** EpiMonitor: Matteo Lai, MSc, Empatica
- 1:40-1:50** Helpilepsy: Jonathan Schreiber, MSc, Neuroventis
- 1:50-2:00** 24/7 EEG SubQ: Kristian Lykke Fick, MSc, UNEEG medical
- 2:00- 2:10** SAMi The Sleep Activity Monitor: Matt Anderson, SAMi
- 2:10-2:20** Eysz Hyperventilation Recorder: Parth Amin, Eysz, Inc.
- 2:20-2:30** NEVOA-AI: Mehrdad Seirafi, PhD, Alpha Brain Technologies B.V.
- 2:30-2:40** REMI: Mark Lehmkuhle, PhD, Epitel
- 2:40-2:50** Emergency / ICU EEG: Aswin Gunasekar, MBA, Zeto
- 2:50-3:05** Networking Break

SHARK TANK COMPETITION

3:05-3:10 Shark Tank Welcome
Jacqueline French, MD, Epilepsy Foundation

3:10-3:20 Shark tank past winners: How have they done? Caitlin Grzeskowiak, PhD, Epilepsy Foundation

3:20-3:30 2023 winner update
Paul Loomis – Braincapture

3:30-3:40 2023 winner update
Angela Liedler – Precisis GmbH

3:40-3:50 Introductions and Rules

Sharks:

Sasha Alick-Lindstrom, MD, UT Southwestern

John Hixson, MD, Neurona Therapeutics

Bee Lee, CEO, Epilepsy Foundation

Wasim Q. Malik, PhD, Iaso Ventures

Robert Smith

3:50 – 4:50 Competition

2024 Shark Tank Finalists

LAMPSY: An Invisible Seizure Detection Device

Vicente Garção, CEO - LAMPSY

Chronic Subgaleal EEG Monitoring Platform

Ruben Kuzniecky, MD, CMO – Neuroview Technology

Theta Neurotech

Truman Pierson, CEO – Theta Neurotech

AI Against Epilepsy

Karine Seymour, CEO – Avrio MedTech

BioEP: A digital biomarker for epilepsy decision support

Professor John Terry – Neuronostics, Ltd

4:50–5:00 Deliberations/Voting

5:00–5:10 Announce Winner

5:10–5:40 AWARD PRESENTATIONS

2024 May Liang & James Lintott Scholarship Recipient

Kristie Bauman, MD, UC Davis

Elaine Sinclair, DO, PhD, NYU

2024 Epilepsy Foundation Lifetime Accelerator Award

Raymond Edward Faught, Jr., MD

5:40 – 6:15 – Networking Break

6:15 NETWORKING RECEPTION

Thursday, September 26th

7:00-8:00 Continental Breakfast and Registration

8:00-8:05 Welcome

SESSION IV: PIPELINE FOR GENE BASED AND CELL THERAPIES

Moderator: Brandy Fureman PhD

8:05-8:10 Patient Caregiver Perspective: Shawn M. Egan, PhD, CEO, FamilieSCN2A Foundation

8:10-8:20 NRTX-1001: John Hixson, MD, Neurona Therapeutics

8:20-8:30 ETX101: Sal Rico, MD, PhD, Encoded Therapeutics

8:30-8:40 Pioneering tRNA Therapeutics to Cure Genetic Diseases: Gregory Robinson, PhD, Tevard Biosciences

8:40-8:50 STK-001 in Dravet Syndrome: Carrie Condon, MPH, Stoke

8:50-9:00 Solidus™: Kris Kahlig, PhD, Praxis Precision Medicines

9:00-9:10 CAP-002: Swati Tole, MD, Capsida Biotherapeutics

9:10-9:20 AMT-260: Arisha Ahmad, uniQure

SESSION V: Pediatric trials

Moderator: Alexis Arzimanoglou MD, PhD

9:20-9:25 Patient/Caregiver Perspective: JayEtta Hecker, MS, International SCN8A Alliance

9:25-9:40 How should we group patients for DEE trials - The path forward: Helen Cross, MD, ILAE

9:40-9:55 RRE updates: Measuring non-seizure outcomes in disease-modifying trials: Madison Berl, PhD, Children's National Hospital

9:55-10:15 Q&A

10:15-10:30 RRE Hot topic: Measuring seizure outcomes for disease modifying trials: Jacqueline French, MD

10:30-10:50 Panel: measuring seizure impact beyond seizure counting: Madison Berl, PhD, Helen Cross, MD, Gail Farfel, PhD, Jacqueline French, MD, Dan Friedman, MD, JayEtta Hecker, MS

10:50-11:05 Discussion

11:05-11:15 Networking Break

SESSION VI: CLINICAL DRUGS

Moderator: Jacqueline French, MD

11:15-11:20 Patient/Caregiver Perspective: Alison Zetterquist

11:20-11:30 Radiprodil: Michael Panzara, MD, MPH, GRIN Therapeutics, A Neurvati Neurosciences Company

11:30-11:40 Bexicaserin: Ian Miller, MD, Longboard Pharmaceuticals

11:40-11:50 Ganaxolone RSE: Joseph Hulihan, MD, Marinus Pharmaceuticals, Inc.

11:50-12:00 PRAX-562: Steven Petrou, PhD, Praxis Precision Medicines, Inc.

12:00-12:10 Rap-219:Arnold Gammaitoni, PharmD, Rapport Therapeutics

12:10-1:10 Networking Lunch

SESSION VII: CLINICAL TRIAL CONDUCT

Moderator: Christopher Elder, MD

1:10-1:15 Patient/Caregiver Perspective: Melissa Maske

1:15-1:25 European Consortium for Epilepsy Trials (ECET): Alexi Arzimanoglou, MD, PhD

1:25-1:40 Why is recruitment getting harder: Daniel Friedman, MD, MSc, NYU Grossman School of Medicine

1:40-2:05 What is causing the placebo response: New Data: Wesley Kerr, MD, PhD, University of Pittsburgh

2:05-2:20 Increasing DEI and trial enrollment: Jonathan Williams, MD, Washington University

2:20-2:40 Panel: Improving recruitment in trials: Alexi Arzimanoglou, MD, PhD; Christopher Elder, MD; Daniel Friedman, MD, MSc; Wesley Kerr, MD, PhD; Melissa Maske; Jonathan Williams, MD

SESSION VIII: CLINICAL DRUGS

Moderator: Raymond Edward Faught, Jr., MD

2:40-2:50 Azetukalner: Monica Dhakar, MD, FAES, Xenon Pharmaceuticals, Inc.

2:50-3:00 BHV 7000: Jason T. Lerner, MD, Biohaven Pharmaceuticals

3:00-3:10 SPN-817: Neeti Mehta, PhD, Supernus Pharmaceuticals

3:10-3:20 EPX-100: George Nomikos, MD, PhD, Harmony Biosciences

3:20-3:30 Staccato Alprazolam: Robert Roebeling, MD, UCB

3:30-3:40 NOE-101: Rosemarie Roeloffs, Noema Pharma

3:40-3:45 Closing Remarks